NCT06906874 Activated Charcoal Use in Chronic Kidney Disease Patients
| NCT ID | NCT06906874 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Mansoura University |
| Condition | End Stage Renal Disease (ESRD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-08 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2025-08 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Eligibility Criteria
Inclusion Criteria: 1. Adult aged ≥18 years with ESRD. 2. Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months. 3. Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO). Exclusion Criteria: 1. Severely malnourished (as diagnosed by the department's dietitian). 2. Treated with overnight dialysis. 3. Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06906874 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying End Stage Renal Disease (ESRD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06906874 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06906874 currently recruiting?
Yes, NCT06906874 is actively recruiting participants. Contact the research team at basma_mohamed@mans.edu.eg for enrollment information.
Where is the NCT06906874 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT06906874 clinical trial?
NCT06906874 is sponsored by Mansoura University. The trial plans to enroll 40 participants.